- NATx Operations Manager Dr. Katelyn Lacy presents at the 10th Annual RNA Symposium
- Core staff “graduate” from Agilent University – Drs. Hala Abou Assi and Michaela Everly completed the four-day “Agilent 6200/6500 Series LC/TOF/Q-TOF Techniques and Operation for Large Molecules” training course at Agilent Technologies in Lexington, MA, where they learned valuable hands-on experience and practical insights into LC/MS for large molecules and oligonucleotide analysis. They are looking forward to applying what they learned at the NATx Core at the University of Michigan!
NATx in the News
$3.9 million NIH grant to fuel U-M effort to develop first targeted therapy for fatal childhood brain disorder
The University of Michigan has received a $3.9 million award from the National Institutes of Health's Ultra-rare Gene-based Therapy (URGenT) Program to develop a novel antisense oligonucleotide (ASO) medicine for CLN3 Batten disease, a rare, fatal genetic disorder.
New research core removes barriers to RNA-based research and drug discovery efforts at U-M
The Nucleic Acids Therapeutics (NATx) Core brings novel nucleic acid–based research functions to the university, one of the first full-service centers of its type in an academic setting.